Skip to content
  1. Home/
  2. Latest news/
  3. What you need to know about Johnson & Johnson’s 2024 third quarter earnings
what-you-need-to-know-about-johnson-johnsons-2024-third-quarter-earnings-1024.png

What you need to know about Johnson & Johnson’s 2024 third quarter earnings

Check out this infographic breakdown of the company’s third quarter performance, with highlights from its Innovative Medicine and MedTech businesses.

This morning, Johnson & Johnson shared its 2024 third quarter earnings report.

Since its founding in 1886 the company has been committed to innovation—today, more than 130,000 employees across the globe work to deliver solutions for patients around the world to help profoundly impact health for humanity.

“Johnson & Johnson’s performance in the third quarter reflects the diversification of our business and forward-looking, disciplined approach as we continue to invest in breakthrough innovation and acquisitions such as V-Wave that further bolster and differentiate our pipeline,” says Joe Wolk, Executive Vice President and Chief Financial Officer, Johnson & Johnson. “As we wind down 2024, we are focused on advancing our pipeline further, positioning the business for continued growth in 2025 and beyond.”

For more details about the company’s 2024 third quarter results and to read a message from Chairman and Chief Executive Officer Joaquin Duato, here’s an infographic highlighting key stats.

2024-third-quarter-earnings-infographic-1024.png

Johnson & Johnson’s 2024 third quarter earnings

Read the earnings press release, which includes full financial data for the third quarter of 2024.

Want to see more company earnings information? Find Johnson & Johnson’s past quarterly and full-year results here.

More from Johnson & Johnson

Johnson & Johnson named to Fortune’s 2025 America’s Most Innovative Companies list

The company’s commitment to developing solutions that tackle the world’s most pressing health challenges has helped Johnson & Johnson be recognized as the top-ranked healthcare company on the list.

Inside Johnson & Johnson’s decades-long quest to develop effective treatments for IBD

Inflammatory bowel disease doesn’t have a cure—yet. But the recent FDA approval of a promising medication is the latest in a long line of treatments from Johnson & Johnson that are helping patients with IBD.

The future of immunology

Learn about the advances Johnson & Johnson is making to potentially help treat the millions of people living with conditions in which the immune system mistakenly damages healthy cells in the body.